Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-499.
Schouten BJ, Brownlie BE, Frampton CM, et al. Subclinical thyrotoxicosis in an outpatient population—predictors of outcome. Clin Endocrinol (Oxf). 2011;74(2):257-261.
Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am. 2006;35(4):663-686.
Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-316.
Martinez Quintero B, Yazbeck C, Sweeney LB. Thyroiditis: evaluation and treatment. Am Fam Physician. 2021;104(6):609-617.
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
Goichot B, Caron P, Landron F, et al. Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationships with age, aetiology and hormonal parameters. Clin Endocrinol (Oxf). 2016;84(3):445-451.
Manji N, Carr-Smith JD, Boelaert K, et al. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab. 2006;91(12):4873-4880.
Bogazzi F, Tomisti L, Di Bello V, et al. Tireotossicosi indotta da amiodarone. [Amiodarone-induced thyrotoxicosis]. G Ital Cardiol (Rome). 2017;18(3):219-229.
Basolo A, Matrone A, Elisei R, et al. Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism. Semin Cancer Biol. 2022;79:197-202.
Donangelo I, Suh SY. Subclinical hyperthyroidism: when to consider treatment. Am Fam Physician. 2017;95(11):710-716.
Boelaert K, Torlinska B, Holder RL, et al. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab. 2010;95(6):2715-2726.
Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry. 2000;68(6):750-755.
Gulseren S, Gulseren L, Hekimsoy Z, et al. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res. 2006;37(1):133-139.
Bode H, Ivens B, Bschor T, et al. Hyperthyroidism and clinical depression: a systematic review and meta-analysis. Transl Psychiatry. 2022;12(1):362.
Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest. 2014;37(8):691-700.
Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012;345:e7895.
Joglar JA, Chung MK, Armbruster AL, et al. ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. J Am Coll Cardiol. 2024;83(1):109-279.
Satoh T, Isozaki O, Suzuki A, et al. 2016 guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition). Endocr J. 2016;63(12):1025-1064.
Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22(2):263-277.
de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. 1989;149(3):526-532.
Thyroid disease in pregnancy: ACOG Practice Bulletin Summary, Number 223. Obstet Gynecol. 2020;135(6):1496-1499.
Tozzoli R, Bagnasco M, Giavarina D, et al. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107-113.
Cheng X, Chai X, Ma C, et al. Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated antiTSHR immunoassay for Graves’ disease: a Chinese multicenter study. Endocrine. 2021;71(1):139-148.
Tanaka T, Tanaka T, Ogo A, et al. Short-term effects of β-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves’ disease. Intern Med. 2012;51(17):2285-2290.
Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.
Ma C, Xie J, Wang H, et al. Radioiodine therapy versus antithyroid medications for Graves’ disease. Cochrane Database Syst Rev. 2016(2):CD010094.
Abraham P, Avenell A, McGeoch SC, et al. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010(1):CD003420.
Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg. 2020;271(3):e21-e93.
Azizi F, Amouzegar A, Tohidi M, et al. Increased remission rates after long-term methimazole therapy in patients with graves’ disease: results of a randomized clinical trial. Thyroid. 2019;29(9):1192-1200.
Kang AS, Grant CS, Thompson GB, et al. Current treatment of nodular goiter with hyperthyroidism (Plummer’s disease): surgery versus radioiodine. Surgery. 2002;132(6):916-923 , discussion 923.
Brito JP, Payne S, Singh Ospina N, et al. Patterns of use, efficacy, and safety of treatment options for patients with Graves’ disease: a nationwide population-based study. Thyroid. 2020;30(3):357-364.
Azizi F, Saadat N, Takyar MA, et al. Efficacy and safety of long-term methimazole versus radioactive iodine in the treatment of toxic multinodular goiter. Endocrinol Metab (Seoul). 2022;37(6):861-869.
Sjölin G, Holmberg M, Törring O, et al. The long-term outcome of treatment for Graves’ hyperthyroidism. Thyroid. 2019;29(11):1545-1557.
Saadat N, Azizi F, Abdi H, et al. Treatment of post-radioactive iodine relapse of hyperthyroidism: comparison of long-term methimazole and radioactive iodine treatment. J Endocrinol Invest. 2022;45(10):1919-1924.
Vija Racaru L, Fontan C, Bauriaud-Mallet M, et al. Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response. Nucl Med Commun. 2017;38(9):756-763.
Azizi F, Smyth P. Breastfeeding and maternal and infant iodine nutrition. Clin Endocrinol (Oxf). 2009;70(5):803-809.
Träisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94(10):3700-3707.
Kravets I. Hyperthyroidism: diagnosis and treatment. Am Fam Physician. 2016;93(5):363-370.
Reid JR, Wheeler SF. Hyperthyroidism: diagnosis and treatment. Am Fam Physician. 2005;72(4):623-630.